| Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis GM Ruiz-Palacios, I Pérez-Schael, FR Velázquez, H Abate, T Breuer, ... New England Journal of Medicine 354 (1), 11-22, 2006 | 2388 | 2006 |
| Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a … AC Linhares, FR Velázquez, I Pérez-Schael, X Sáez-Llorens, H Abate, ... The Lancet 371 (9619), 1181-1189, 2008 | 466 | 2008 |
| Efficacy of a tetravalent dengue vaccine in healthy children and adolescents S Biswal, H Reynales, X Saez-Llorens, P Lopez, C Borja-Tabora, ... New England Journal of Medicine 381 (21), 2009-2019, 2019 | 373 | 2019 |
| Intimacy as an interpersonal process: Current status and future directions JP Laurenceau, LM Rivera, AR Schaffer, PR Pietromonaco Handbook of closeness and intimacy, 71-88, 2004 | 280 | 2004 |
| From automatic antigay prejudice to behavior: The moderating role of conscious beliefs about gender and behavioral control. N Dasgupta, LM Rivera Journal of personality and social psychology 91 (2), 268, 2006 | 277 | 2006 |
| Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial S Biswal, C Borja-Tabora, LM Vargas, H Velásquez, MT Alera, V Sierra, ... The Lancet 395 (10234), 1423-1433, 2020 | 272 | 2020 |
| When social context matters: The influence of long–term contact and short–term exposure to admired outgroup members on implicit attitudes and behavioral intentions N Dasgupta, LM Rivera Social Cognition 26 (1), 112-123, 2008 | 231 | 2008 |
| “My child has a sleep problem”: a cross-cultural comparison of parental definitions A Sadeh, J Mindell, L Rivera Sleep medicine 12 (5), 478-482, 2011 | 215 | 2011 |
| Hepatitis A in Latin America: a changing epidemiologic pattern. R Tapia-Conyer, JI Santos, AM Cavalcanti, E Urdaneta, L Rivera, ... The American journal of tropical medicine and hygiene 61 (5), 825-829, 1999 | 203 | 1999 |
| Three-year efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003) L Rivera, S Biswal, X Sáez-Llorens, H Reynales, E López-Medina, ... Clinical Infectious Diseases 75 (1), 107-117, 2022 | 194 | 2022 |
| Vaccine for prevention of mild and moderate-to-severe influenza in children VK Jain, L Rivera, K Zaman, RA Espos Jr, C Sirivichayakul, BP Quiambao, ... New England Journal of Medicine 369 (26), 2481-2491, 2013 | 145 | 2013 |
| Hepatitis B seroprevalence in Latin America TR Silveira, JC Fonseca, L Rivera, OH Fay, R Tapia, JI Santos, ... Revista Panamericana de Salud Pública 6, 378-383, 1999 | 136 | 1999 |
| Racism and social capital: The implications for social and physical well‐being E Brondolo, M Libretti, L Rivera, KM Walsemann Journal of Social Issues 68 (2), 358-384, 2012 | 134 | 2012 |
| Cuidado humanizado de enfermería: visibilizando la teoría y la investigación en la práctica, en la Clínica del Country L Rivera, Á Triana Actual Enferm 10 (4), 15-21, 2007 | 129 | 2007 |
| Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial V Tricou, X Sáez-Llorens, D Yu, L Rivera, J Jimeno, AC Villarreal, E Dato, ... The Lancet 395 (10234), 1434-1443, 2020 | 126 | 2020 |
| Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity M Muñoz, ME López-Oliva, C Rodríguez, MP Martínez, J Sáenz-Medina, ... Redox biology 28, 101330, 2020 | 124 | 2020 |
| Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination E López-Medina, S Biswal, X Saez-Llorens, C Borja-Tabora, L Bravo, ... The Journal of infectious diseases 225 (9), 1521-1532, 2022 | 103 | 2022 |
| Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised … X Sáez-Llorens, V Tricou, D Yu, L Rivera, S Tuboi, P Garbes, A Borkowski, ... The Lancet Infectious Diseases 17 (6), 615-625, 2017 | 103 | 2017 |
| Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a … X Sáez-Llorens, V Tricou, D Yu, L Rivera, J Jimeno, AC Villarreal, E Dato, ... The Lancet infectious diseases 18 (2), 162-170, 2018 | 102 | 2018 |
| Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4· 5-year results from a phase 3, randomised, double-blind, placebo-controlled trial V Tricou, D Yu, H Reynales, S Biswal, X Saez-Llorens, C Sirivichayakul, ... The Lancet Global Health 12 (2), e257-e270, 2024 | 92 | 2024 |
